乙氨基在重症监护室的作用 痴呆症预防:一项回顾性队列研究
Somnath Bose1, Béla-Simon Paschold2,3, Tahereh Shamsi2
1Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, Massachusetts, United States; sbose2@bidmc.harvard.edu.
Annals of the American Thoracic Society
|August 4, 2025
概括
乙氨基的使用显著降低了重症监护室 (ICU) 患者的妄想发作的发生率. 观察到一种剂量依赖的关系,较高的乙氨基使用与较少的妄想时间相关.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
背景情况:
- 在重症监护室 (ICU) 患者的 Delirium 与疼痛,全身炎症和不良结果有关.
- 乙氨基降低妄想发病率的潜力需要在术后环境之外进行进一步的研究.
研究的目的:
- 调查乙氨基的使用与ICU患者 Delirium 的发生率之间的关联.
- 探索乙氨基暴露和妄想发生之间的剂量依赖关系.
主要方法:
- 对17,818名成年ICU患者 (2015-2024) 的回顾性队列研究.
- 主要暴露:乙氨基的使用 (≥2g/天).
- 主要结局:ICU狂妄发病率,通过混评估方法-ICU进行评估.
主要成果:
- 乙氨基使用与的发病率降低有关 (ORadj 0.66,p<0.001).
- 一个剂量依赖的关联显示,妄时间缩短,乙氨基暴露增加,在≥40%的覆盖率下停滞.
- 绝对风险降低在狂妄症是6.0%与乙氨基.
结论:
- 乙氨基与重症病患在ICU狂妄症的显著减少有关.
- 在乙氨基的影响下的时间比例与妄想持续时间相反相关.
- 建议通过随机对照试验进行进一步验证.
相关概念视频
Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Psychosis: Goals of Pharmacotherapy
209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
CNS Depressants: Barbiturates and Benzodiazepines
471
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
471
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
Parenteral Anesthetics: Overview
199
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
199


